Cargando…
Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal
BACKGROUND: The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we determi...
Autores principales: | Huijgen, Roeland, Kindt, Iris, Verhoeven, Sjoerd B. J., Sijbrands, Eric J. G., Vissers, Maud N., Kastelein, John J. P., Hutten, Barbara A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821409/ https://www.ncbi.nlm.nih.gov/pubmed/20169164 http://dx.doi.org/10.1371/journal.pone.0009220 |
Ejemplares similares
-
Quality Assessment of the Genetic Test for Familial Hypercholesterolemia in The Netherlands
por: Kindt, Iris, et al.
Publicado: (2013) -
Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes
por: Kusters, D. M., et al.
Publicado: (2011) -
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
por: Stoekenbroek, Robert M., et al.
Publicado: (2015) -
Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence
por: Braamskamp, Marjet J. A. M., et al.
Publicado: (2015) -
Optimizing Treatment of Familial Hypercholesterolemia in Children and Adolescents
por: Luirink, Ilse K., et al.
Publicado: (2015)